Rx Product News (March 2016)

Pharmacy Times, March 2016 Central Nervous System, Volume 82, Issue 3

Read about the new Rx Products featured in March.

Biocryst Pharmaceuticals, Inc

Indication: The FDA has approved Rapivab (peramivir), an influenza virus neuraminidase inhibitor, for the treatment of acute uncomplicated influenza in adults who have been symptomatic for no more than 2 days. The recommended dosage is a single dose of 600 mg administered by intravenous infusion for a minimum of 15 minutes within 2 days of the onset of influenza symptoms. The dosage should be reduced to 200 mg for patients with a baseline creatinine clearance of 30 to 49 mL/min, and reduced to 100 mg for patients with a baseline creatinine clearance of 10 to 29 mL/min.

Dosage Form: Injection: 200 mg in 20 mL (10 mg/mL) in a single-use vial

For More Information: www.rapivab.com

CosentyxMarketed by: Novartis Pharmaceuticals

Indication: The FDA has approved Cosentyx (secukinumab), a human interleukin-17A antagonist, for the treatment of adults with active ankylosing spondylitis or active psoriatic arthritis. For the recommended dosages, see the full prescribing information.

Dosage Form: Injection: 150-mg/mL solution in a single- use pen or prefilled syringe, or 150 mg of lyophilized powder in a single-use vial for reconstitution

For More Information: cosentyx.com

BasaglarMarketed by: Eli Lilly and Company

Indication: The FDA has approved Basaglar (insulin glargine injection), a long-acting human insulin analog, for improving glycemic control in adults and pediatric patients with type 1 diabetes mellitus, and in adults with type 2 diabetes mellitus. The dosage should be individualized based on metabolic needs, blood glucose monitoring, glycemic control, type of diabetes, and prior insulin use. Basaglar should be administered subcutaneously once daily at any time of day, but at the same time every day.

Dosage Form: Injection: 100 units/ mL (U-100) in 3-mL prefilled Basaglar KwikPen delivery device

For More Information: basaglar.com

QuilliChew ERMarketed by: Pfizer

Indication: The FDA has approved QuilliChew ER (methylphenidate hydrochloride), a central nervous system (CNS) stimulant, for the treatment of attention-deficit/ hyperactivity disorder. For patients 6 years and older, the recommended starting dose is 20 mg orally, once daily in the morning. The dosage may be titrated weekly in increments of 10 mg, 15 mg, or 20 mg per day. A daily dosage above 60 mg is not recommended.

Dosage Form: Extended-release chewable tablets: 20 mg and 30 mg of methylphenidate hydrochloride (HCl), functionally scored Extended-release chewable tablets: 40 mg of methylphenidate HCl, not scored

For More Information: pfizer.com/products/product-detail/ quillichew_er

OtiprioMarketed by: Otonomy, Inc

Indication: The FDA has approved Otiprio (ciprofloxacin otic suspension), a fluoroquinolone antibacterial, for the treatment of pediatric patients with bilateral otitis media with effusion who are undergoing tympanostomy tube placement. Otiprio should be administered as a single intratympanic dose of one 0.1-mL (6 mg) into each affected ear, following suctioning of middle ear effusion.

Dosage Form: Otic suspension: Each Otiprio vial contains 1 mL of 6% (60 mg/mL) ciprofloxacin otic suspension

For More Information: otiprio.com